Literature DB >> 7899293

[Dysthyroidism in patients treated with interferon alpha].

P Chédin1, P Chanson, L Duranteau, P J Guillausseau, J Lubetzki.   

Abstract

In addition to their initially recognized antiviral activity, interferons are known to have a number of effects on the immune system. The role of alpha-interferon (alpha-IFN) has been evaluated in 8 studies, including 573 patients, aimed at determining the prevalence, clinical course and predictive factors of autoimmune dysthyroidism in patients treated with alpha-IFN. Two major categories of patients were treated with alpha-IFN: those with cancer and those with chronic viral hepatitis. Two types of interferon were used: human leukocyte IFN and recombinant IFN. Among the 542 patients in which thyroid function was evaluated, 47 (8.7%) had clinical or biological dysthyroidism: hypothyroidism in 25 (53%), hyperthyroidism in 13 (28%) and biphasic hyper-hypothyroidism in 9 (19%). The delay to onset was known in 44 patients (mean 9 months, range 1.5 to 23 months). Dysthyroidism was temporary in certain patients and did not require treatment, but antithyroid drugs were required in others. The prevalence of antithyroglobulin and/or antimicrosomal antibodies varied from 0 to 20% (mean 13.7%). The prevalence of antithyroid stimulating hormone receptor antibodies appeared to be lower than that of antithyroid antibodies. The pathogenic mechanism of dysthyroidism in patients given alpha-IFN remains unknown, but could result from the induction of antithyroid antibodies or an increase in pre-existing levels. Abherent expression of HLA-DR antigens on the surface of the thyrocytes has been proposed as a possible factor, although gamma-IFN and not alpha-IFN leads to the expression of class II antigens. It has also been shown that alpha-IFN induces the expression of class I antigens on thyrocytes, indicating that the observed dysthyroidism might result from an over-expression of class I antigens which would facilitate direct activation of cytotoxic T cells. In summary, alpha-IFN can induce dysthyroidism in about 1 out of 10 patients, probably by the induction or stimulation of autoimmune phenomena. The positive predictive value of antithyroid antibodies is modest, about 60%, but the negative predictive value is high at 93%. Thyroid function should be monitored closely in patients given alpha-interferon.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7899293

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  3 in total

1.  Occurrence of thyroid autoimmunity in relapsing remitting multiple sclerosis patients undergoing interferon-beta treatment.

Authors:  V Martinelli; M Gironi; M Rodegher; G Martino; G Comi
Journal:  Ital J Neurol Sci       Date:  1998-04

2.  Evolution and predictive factors of thyroid disorder due to interferon alpha in the treatment of hepatitis C.

Authors:  Moana Gelu-Simeon; Aurore Burlaud; Jacques Young; Gilles Pelletier; Catherine Buffet
Journal:  World J Gastroenterol       Date:  2009-01-21       Impact factor: 5.742

Review 3.  Interferon alpha treatment and endocrine disease.

Authors:  Wing Bun Chan; Chun Chung Chow; Clive Stewart Cockram
Journal:  J R Soc Med       Date:  2003-10       Impact factor: 18.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.